Mobility Training in Blood Disorders: Evidence, Mechanisms, and Clinical Practice

Abstract

Mobility training is increasingly recognized as a cornerstone in the multidisciplinary management of patients with blood disorders. This review synthesizes current evidence on the role of structured mobility interventions across various hematological conditions, including hemophilia, sickle cell disease, and leukemia, focusing on pathophysiological considerations, clinical features, risk stratification, and outcome optimization. Recent guideline updates and emerging therapies are discussed, highlighting the evolving landscape of rehabilitation in hematology. The article aims to provide clinicians and healthcare professionals with a comprehensive understanding of evidence-based mobility training strategies and their integration into routine clinical care.

Introduction

Blood disorders encompass a diverse group of conditions, many of which profoundly impact patients’ physical function, musculoskeletal health, and quality of life. Mobility limitations, whether due to arthropathy in hemophilia, vaso-occlusive crises in sickle cell disease, or treatment-induced deconditioning in leukemia, are a common clinical challenge. Advances in medical management have improved survival rates, making the long-term functional outcomes of mobility training increasingly relevant. This review explores the scientific basis, clinical rationale, and practical implementation of mobility training in blood disorders, providing targeted insights for medical professionals managing these complex patients.

Epidemiology / Disease Burden

Globally, blood disorders affect millions, with hemophilia A and B having an estimated prevalence of 1 in 10,000 and 1 in 25,000 male births, respectively. Sickle cell disease affects approximately 20–25 million individuals worldwide, particularly prevalent in sub-Saharan Africa, India, and the Middle East. Leukemia, the most common childhood cancer, continues to rise in incidence. The burden of mobility impairment in these populations is substantial, leading to increased healthcare utilization, reduced participation in daily activities, and diminished overall quality of life. Epidemiological studies consistently demonstrate that up to 60% of adults with severe hemophilia experience activity limitations, and nearly 80% of sickle cell disease patients report some level of ambulatory restriction during their lifetime.

Pathophysiology

The pathophysiological mechanisms underlying mobility impairment in blood disorders are multifactorial. In hemophilia, recurrent hemarthroses lead to synovial inflammation, cartilage degradation, and ultimately chronic hemophilic arthropathy, which severely restricts joint range of motion. Sickle cell disease is characterized by recurrent vaso-occlusive episodes resulting in avascular necrosis, myopathy, and neuropathy, all contributing to reduced mobility. Leukemia and its treatments, such as chemotherapy and corticosteroids, induce muscle wasting, neuropathy, and bone demineralization, further exacerbating movement difficulties. Understanding these mechanisms is critical for designing targeted mobility interventions and preventing irreversible disability.

Risk Factors

Risk factors for mobility impairment in blood disorders include disease severity, frequency of acute complications (e.g., joint bleeds in hemophilia, pain crises in sickle cell disease), age at disease onset, treatment adherence, and comorbidities such as obesity or peripheral neuropathy. Notably, the risk of joint damage in hemophilia correlates with delayed or suboptimal prophylactic therapy, while in sickle cell disease, high cumulative pain event frequency and chronic anemia are key predictors of impaired function. Early identification of at-risk individuals enables timely intervention and individualized mobility training programs.

Clinical Features

Mobility limitations in blood disorders manifest as reduced gait speed, altered joint biomechanics, muscle weakness, decreased endurance, and impaired balance. Hemophilia patients typically present with recurrent hemarthroses, particularly affecting the knees, ankles, and elbows, leading to joint contractures and muscle atrophy. In sickle cell disease, musculoskeletal pain, avascular necrosis of the femoral head, and leg ulcers are common contributors to ambulation difficulties. Leukemia survivors may experience prolonged fatigue, steroid-induced myopathy, and neuropathic gait disturbances. Comprehensive clinical evaluation includes functional assessments such as the 6-minute walk test, joint range of motion measurements, and validated patient-reported outcome measures.

Diagnosis

Diagnosis of mobility impairment in blood disorders requires a multidisciplinary approach involving hematologists, physiatrists, physical therapists, and orthopedic specialists. Clinical evaluation is complemented by imaging studies, such as ultrasound for joint effusion in hemophilia, MRI for avascular necrosis in sickle cell disease, and DEXA scanning for bone mineral density in leukemia. Laboratory parameters (e.g., factor levels, hemoglobin concentration) and functional outcome tools (e.g., Hemophilia Joint Health Score, Functional Mobility Scale) provide objective measures to guide intervention planning and monitor progress.

Treatment & Management

Mobility training in blood disorders is tailored to individual needs, disease severity, and functional status. Interventions include targeted physical therapy, muscle strengthening, joint range of motion exercises, gait training, and balance enhancement. Prophylactic factor replacement in hemophilia enables safer participation in exercise programs, while hydroxyurea therapy in sickle cell disease reduces the frequency of pain crises, facilitating rehabilitation. Close monitoring for bleeding, pain, and fatigue is essential, with adjustments to intensity and modality as needed. Multidisciplinary rehabilitation teams play a pivotal role in optimizing outcomes and promoting adherence.

Recent Advances / Emerging Therapies

Recent advances in pharmacological and non-pharmacological therapies have transformed the landscape of mobility training in blood disorders. Extended half-life clotting factors, gene therapy, and non-factor replacement agents (e.g., emicizumab) have reduced bleeding risk in hemophilia, permitting more intensive and proactive mobility interventions. In sickle cell disease, novel agents such as voxelotor and crizanlizumab, alongside improvements in pain management protocols, enable earlier and more effective rehabilitation. Digital health tools, wearable sensors, and tele-rehabilitation platforms are increasingly integrated into mobility training, allowing for remote monitoring, real-time feedback, and individualized progression.

Guideline Recommendations

Consensus guidelines from organizations such as the World Federation of Hemophilia, American Society of Hematology, and National Institutes of Health emphasize early and ongoing mobility assessment, individualized exercise prescription, and the importance of multidisciplinary care. Key recommendations include routine functional evaluation, use of validated outcome measures, patient and caregiver education regarding safe activity participation, and integration of mobility training into comprehensive disease management plans. These guidelines underscore the necessity of balancing physical activity benefits with risk mitigation strategies.

Conclusion

Mobility training is a clinically essential, evidence-based intervention for patients with blood disorders, addressing both pathophysiological and functional challenges. Advances in pharmacotherapy and rehabilitation science have expanded the therapeutic window for safe and effective mobility interventions. Ongoing research, guideline refinement, and interdisciplinary collaboration are vital to optimizing functional outcomes and enhancing quality of life in this growing patient population. Clinicians should remain vigilant for new evidence and integrate best practices into personalized care pathways for individuals living with blood disorders.